Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly

Keita Kirito, Kenshi Suzuki, Koichi Miyamura, Masahiro Takeuchi, Hiroshi Handa, Shinichiro Okamoto, Brian Gadbaw, Kyosuke Yamauchi, Taro Amagasaki, Kazuo Ito, Masayuki Hino

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Ruxolitinib, a potent JAK1/JAK2 inhibitor, was found to be superior to the best available therapy (BAT) in controlling hematocrit, reducing splenomegaly, and improving symptoms in the phase 3 RESPONSE study of patients with polycythemia vera with splenomegaly who experienced an inadequate response to or adverse effects from hydroxyurea. We report findings from a subgroup analysis of Japanese patients in RESPONSE (n = 18). The composite response rate (hematocrit control and spleen response) was higher in patients receiving ruxolitinib (50.0%) than in those receiving BAT (8.3%). A total of 50.0% of patients randomized to ruxolitinib achieved a spleen response vs 8.3% of those receiving BAT; 100 and 33.3% of patients in the respective groups achieved hematocrit control, with mean hematocrit in ruxolitinib-treated patients remaining stable at < 45% throughout the study. Similarly, a higher proportion of ruxolitinib-treated patients achieved complete hematologic remission (33.3 vs 16.7%). Ruxolitinib also led to rapid improvements in pruritus. All responses with ruxolitinib were durable to week 80, and its safety profile was consistent with that in the overall study. These findings suggest that ruxolitinib is an effective and well-tolerated treatment option for Japanese patients with polycythemia vera with an inadequate response to or adverse effects from hydroxyurea.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalInternational Journal of Hematology
DOIs
Publication statusAccepted/In press - 2017 Sep 27

Fingerprint

Polycythemia Vera
Hydroxyurea
Splenomegaly
Hematocrit
Spleen
INCB018424
Therapeutics
Pruritus
Safety

Keywords

  • Hematocrit
  • JAK inhibitor
  • Japan
  • Polycythemia vera
  • Ruxolitinib

ASJC Scopus subject areas

  • Hematology

Cite this

Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly. / Kirito, Keita; Suzuki, Kenshi; Miyamura, Koichi; Takeuchi, Masahiro; Handa, Hiroshi; Okamoto, Shinichiro; Gadbaw, Brian; Yamauchi, Kyosuke; Amagasaki, Taro; Ito, Kazuo; Hino, Masayuki.

In: International Journal of Hematology, 27.09.2017, p. 1-12.

Research output: Contribution to journalArticle

Kirito, Keita ; Suzuki, Kenshi ; Miyamura, Koichi ; Takeuchi, Masahiro ; Handa, Hiroshi ; Okamoto, Shinichiro ; Gadbaw, Brian ; Yamauchi, Kyosuke ; Amagasaki, Taro ; Ito, Kazuo ; Hino, Masayuki. / Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly. In: International Journal of Hematology. 2017 ; pp. 1-12.
@article{7e1de706fead424389a01aa060651082,
title = "Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly",
abstract = "Ruxolitinib, a potent JAK1/JAK2 inhibitor, was found to be superior to the best available therapy (BAT) in controlling hematocrit, reducing splenomegaly, and improving symptoms in the phase 3 RESPONSE study of patients with polycythemia vera with splenomegaly who experienced an inadequate response to or adverse effects from hydroxyurea. We report findings from a subgroup analysis of Japanese patients in RESPONSE (n = 18). The composite response rate (hematocrit control and spleen response) was higher in patients receiving ruxolitinib (50.0{\%}) than in those receiving BAT (8.3{\%}). A total of 50.0{\%} of patients randomized to ruxolitinib achieved a spleen response vs 8.3{\%} of those receiving BAT; 100 and 33.3{\%} of patients in the respective groups achieved hematocrit control, with mean hematocrit in ruxolitinib-treated patients remaining stable at < 45{\%} throughout the study. Similarly, a higher proportion of ruxolitinib-treated patients achieved complete hematologic remission (33.3 vs 16.7{\%}). Ruxolitinib also led to rapid improvements in pruritus. All responses with ruxolitinib were durable to week 80, and its safety profile was consistent with that in the overall study. These findings suggest that ruxolitinib is an effective and well-tolerated treatment option for Japanese patients with polycythemia vera with an inadequate response to or adverse effects from hydroxyurea.",
keywords = "Hematocrit, JAK inhibitor, Japan, Polycythemia vera, Ruxolitinib",
author = "Keita Kirito and Kenshi Suzuki and Koichi Miyamura and Masahiro Takeuchi and Hiroshi Handa and Shinichiro Okamoto and Brian Gadbaw and Kyosuke Yamauchi and Taro Amagasaki and Kazuo Ito and Masayuki Hino",
year = "2017",
month = "9",
day = "27",
doi = "10.1007/s12185-017-2333-y",
language = "English",
pages = "1--12",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly

AU - Kirito, Keita

AU - Suzuki, Kenshi

AU - Miyamura, Koichi

AU - Takeuchi, Masahiro

AU - Handa, Hiroshi

AU - Okamoto, Shinichiro

AU - Gadbaw, Brian

AU - Yamauchi, Kyosuke

AU - Amagasaki, Taro

AU - Ito, Kazuo

AU - Hino, Masayuki

PY - 2017/9/27

Y1 - 2017/9/27

N2 - Ruxolitinib, a potent JAK1/JAK2 inhibitor, was found to be superior to the best available therapy (BAT) in controlling hematocrit, reducing splenomegaly, and improving symptoms in the phase 3 RESPONSE study of patients with polycythemia vera with splenomegaly who experienced an inadequate response to or adverse effects from hydroxyurea. We report findings from a subgroup analysis of Japanese patients in RESPONSE (n = 18). The composite response rate (hematocrit control and spleen response) was higher in patients receiving ruxolitinib (50.0%) than in those receiving BAT (8.3%). A total of 50.0% of patients randomized to ruxolitinib achieved a spleen response vs 8.3% of those receiving BAT; 100 and 33.3% of patients in the respective groups achieved hematocrit control, with mean hematocrit in ruxolitinib-treated patients remaining stable at < 45% throughout the study. Similarly, a higher proportion of ruxolitinib-treated patients achieved complete hematologic remission (33.3 vs 16.7%). Ruxolitinib also led to rapid improvements in pruritus. All responses with ruxolitinib were durable to week 80, and its safety profile was consistent with that in the overall study. These findings suggest that ruxolitinib is an effective and well-tolerated treatment option for Japanese patients with polycythemia vera with an inadequate response to or adverse effects from hydroxyurea.

AB - Ruxolitinib, a potent JAK1/JAK2 inhibitor, was found to be superior to the best available therapy (BAT) in controlling hematocrit, reducing splenomegaly, and improving symptoms in the phase 3 RESPONSE study of patients with polycythemia vera with splenomegaly who experienced an inadequate response to or adverse effects from hydroxyurea. We report findings from a subgroup analysis of Japanese patients in RESPONSE (n = 18). The composite response rate (hematocrit control and spleen response) was higher in patients receiving ruxolitinib (50.0%) than in those receiving BAT (8.3%). A total of 50.0% of patients randomized to ruxolitinib achieved a spleen response vs 8.3% of those receiving BAT; 100 and 33.3% of patients in the respective groups achieved hematocrit control, with mean hematocrit in ruxolitinib-treated patients remaining stable at < 45% throughout the study. Similarly, a higher proportion of ruxolitinib-treated patients achieved complete hematologic remission (33.3 vs 16.7%). Ruxolitinib also led to rapid improvements in pruritus. All responses with ruxolitinib were durable to week 80, and its safety profile was consistent with that in the overall study. These findings suggest that ruxolitinib is an effective and well-tolerated treatment option for Japanese patients with polycythemia vera with an inadequate response to or adverse effects from hydroxyurea.

KW - Hematocrit

KW - JAK inhibitor

KW - Japan

KW - Polycythemia vera

KW - Ruxolitinib

UR - http://www.scopus.com/inward/record.url?scp=85030113722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030113722&partnerID=8YFLogxK

U2 - 10.1007/s12185-017-2333-y

DO - 10.1007/s12185-017-2333-y

M3 - Article

C2 - 28956263

AN - SCOPUS:85030113722

SP - 1

EP - 12

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

ER -